• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Oral HIV preexposure prophylaxis limits willingness to pay for long-acting injectable prophylaxis

byDavid XiangandHarsh Shah
February 14, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared with generic oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), long-acting injectable cabotegravir (CAB-LA) increased life expectancy by 28,000 QALYs.

2. In PrEP-eligible populations, CAB-LA could achieve incremental cost-effectiveness ratios of at most $100,000 per QALY compared to generic F/TDF.

Evidence Rating Level: 2 (Good)

Study Rundown: The HIV Prevention Trials Network 083 trial demonstrated superior effectiveness for HIV pre-exposure prophylaxis when using CAB-LA compared to daily oral F/TDF for men who have sex with men and transgender women. However, with various pricing models, including generic and branded F/TDF, there is a gap in knowledge as to understanding how much society should be willing to pay for the improved effectiveness of CAB-LA over both branded and generic F/TDF options. This study found that the incremental clinical benefits of CAB-LA would not justify a large price difference compared with F/TDF, especially the generic brand which is substantially less expensive than the branded version. This study was limited by uncertainties of future HIV transmissions and the lack of data to incorporate potential changes in quality of life while receiving oral or long-acting PrEP. Nevertheless, these study’s findings are significant, as they demonstrate that though CAB-LA may offer superior clinical benefits, with the presence of highly effective and affordable oral PrEP alternatives, this limits the additional price that society should be willing to pay for CAB-LA.

Click to read the study in AIM

Relevant Reading: Determining the Most Appropriate Use of Available Regimens for HIV Preexposure Prophylaxis

In-Depth [cost-effectiveness analysis]: This cost-effectiveness analysis utilized the cost-effectiveness of preventing AIDS complications model, a validated state-transition microsimulation model of HIV prevention and treatment. Persons with HIV incidences were included in the study whereas persons who discontinued participation in a PrEP program were excluded from the study. Estimated HIV incidence was as follows: 5.32, 1.33, and 0.26 per 100 person-years for off PrEP, generic F/TDF and branded F/TDF, and CAB-LA, respectively. Annual base-case drug costs were as follows: $360 and $16 800 for generic F/TDF and branded F/TAF. The primary outcome measured was quality-adjusted life-years (QALYs), costs (2020 US dollars), incremental cost-effectiveness ratios (ICERs), and maximum price premium for CAB-LA versus F/TDF. Outcomes in the primary analysis were assessed via sensitivity and scenario analyses. In the case-based analysis, CAB-LA increased life expectancy by 28,000 QALYs compared to generic or branded F/TDF. At ten years, CAB-LA had an ICER of at most $100,000 per QALY compared to generic F/TDF at a maximum price premium of $3700 per year over generic F/TDF (if CAB-LA price <$4100 a year). In the sensitivity analysis, CABA-LA could achieve an ICER of $100 000 per QALY versus generic F/TDF at a maximum price premium of $1100 per year over generic F/TDF. Using simulation models, CAB-LA would only provide good value for money if its annual price was less than $3000 to $6600 higher than generic F/TDF. Therefore, CAB-LA should be priced to compete with generic PrEP, not branded PrEP. Overall, this study demonstrates that though CAB-LA may be clinically superior, the return on investment may not justify a switch from low-priced, well-tolerated, generic, oral alternatives, depending on how CAB-LA is priced.

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Several factors influence health programs conducted in the African American Church

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: branded drugsCabotegravircost-effectiveemtricitabinegeneric drugsHIVpre-exposure prophylaxis (PrEPtenofovir disoproxil fumarate
Previous Post

Venous thromboembolism rates in hospitalized children continue to rise

Next Post

Immediate drainage of infected necrotizing pancreatitis shows no benefit over postponed drainage

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

March 29, 2022
Increased frailty associated with childhood cancer survivorship
Oncology

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

March 27, 2022
Next Post
Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis

Immediate drainage of infected necrotizing pancreatitis shows no benefit over postponed drainage

Patient Basics: Cervical Cancer

Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival

2 Minute Medicine Rewind October 12 – 19, 2014

Absence of coronary plaque among symptomatic patients with high low-density lipoprotein cholesterol levels associated with low risk of atherosclerotic cardiovascular disease events

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.